Short interest for Pennant Park Investment gives investors a sense of the degree to which investors are betting on the decline of Pennant Park Investment's stock. Short interest data is updated every two weeks.

Pennant Park Investment Stock (NYSE:PNNT), Short Interest Report

Pennant Park Investment

Pennant Park Inv

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

News

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

NSSC

PNNT


	Citigroup cut the price target for  The Walt Disney Company  (NYSE: DIS) from $145 to $130. Citigroup analyst Jason Bazinet maintained a Buy rating on the stock. Disney shares rose 0.3% to $108.42 in pre-market trading.


Salesforce To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday

Penny Stocks

Short Sellers

Movers

AKBA

APVO

AQST

AVCT

AYRO

BALY

BILI

BLNK

BYSI

CBAT

CELP

CIIC

CORT

COTY

EBON

FENG

FIII

FLUX

FTSI

FUTU

GPOR

GPRO

HUSN

IPWR

JMIA

KNDI

Kintara Therapeutics, Inc. - Common Stock

KTRA

KZIA

LMNL

MDGS

MDVL

MGNI

MGTX

NAKD

NBEV

NETE

NNDM

NUAN

OLMA

OPNT

QIWI

SCYX

SMTS

SOLO

SONO

TANH

TCDA

TIGR

VERI

VJET

VVPR

Gainers


	Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) gained 157.9% to close at $49.00 after the company priced its IPO at $19 per share.


68 Biggest Movers From Yesterday

Intraday Update

ACCO

ACHC

ACRE

ADIL

ADNT

ADOM

ADTN

ADUS

AFIN

AGCO

AGNC

AGRO

AGYS

AIMC

AINV

ALKS

ALLY

ALTM

ALYA

AMAL

AMBC

AMCX

AMPY

ANAT

ANIK

APLS

APOG

APTV

APTX

APWC

ARCC

ARCO

ARDC

ARGO

ARNC

AROC

ASGN

ATAX

ATEN

ATKR

ATNX

ATRA

Stocks That Hit 52-Week Lows On Wednesday

PennantPark Investment Corporation Common Stock

Pennant Park Investment Corp

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.22 by 9.09 percent. The company reported quarterly sales of $34.34 million which beat the analyst consensus estimate of $32.74 million by 4.89 percent. This is a 14.59 percent increase over sales of $29.96 million the same period last year.

Earnings

Earnings Beats

Pennant Park Investment Q1 2024 GAAP EPS $0.24 Beats $0.22 Estimate, Sales $34.34M Beat $32.74M Estimate

ACLS

ALCO

APPS

ASND

AVXL

AZTA

BABA

BARK

BERY

BLBD

CDAY

CENT

CENTA

CFLT

CMRE

CRTO

CSGS

EEFT

ENTA

EQNR

FLNC

FLNG

FORM

FOXA

GEOS

GPRE

HAIN

INTR

MCFT

MKSI

MPWR

MSGE

MTRX

NBIX

NOTV

NTGR

NVST

NWSA

OESX

ORLY

OSCR

PAHC

Earnings Scheduled For February 7, 2024

Thursday marks the last chance for investors to receive the next dividend payout from Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>). 
<h3>What's Happening</h3>
The company announced on Wednesday that it would pay shareholders a monthly dividend of 7 cents per share. On Friday, Pennant Park Investment will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 7 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Friday. Shareholders who own PNNT as of the end of Thursday's session are eligible to receive the 7 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on February 01, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
<a href="https://www.benzinga.com/quote/PNNT">See current stock movements Pennant Park Investment on Benzinga.</a>

Dividends

Pennant Park Investment's Ex-Dividend Date Is Friday, Here's What You Need To Know

Raymond James analyst Robert Dodd maintains Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) with a Outperform and raises the price target from $7.25 to $7.5.

Raymond James Maintains Outperform on Pennant Park Investment, Raises Price Target to $7.5

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.22 by 9.09 percent. This is a 71.43 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $34.04 million which missed the analyst consensus estimate of $34.83 million by 2.26 percent. This is a 17.67 percent increase over sales of $28.93 million the same period last year.

Earnings Misses

Pennant Park Investment Q4 EPS $0.24 Beats $0.22 Estimate, Sales $34.04M Miss $34.83M Estimate

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Wednesday, November 15, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Pennant Park Investment beat estimated earnings by 9.09%, reporting an EPS of $0.24 versus an estimate of $0.22.
Revenue was up $5.11 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 3.9% increase in the share price the next day.
Here's a look at Pennant Park Investment's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.29</td>
<td>0.20</td>
<td>0.19</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.26</td>
<td>0.16</td>
<td>0.14</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>36.59M</td>
<td>31.83M</td>
<td>29.99M</td>
<td>27.15M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>45.01M</td>
<td>36.35M</td>
<td>29.96M</td>
<td>28.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Pennant Park Investment Q4 Earnings

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is set to give its latest quarterly earnings report on Wednesday, 2023-11-15. Here's what investors need to know before the announcement.
Analysts estimate that Pennant Park Investment will report an earnings per share (EPS) of $0.22. 
Pennant Park Investment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 3.9% increase in the share price the next day.
Here's a look at Pennant Park Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.29</td>
<td>0.20</td>
<td>0.19</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.35</td>
<td>0.26</td>
<td>0.16</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.9%</td>
<td>5.86%</td>
<td>-8.35%</td>
<td>-0.49%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699974054_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Pennant Park Investment were trading at $6.65 as of November 13. Over the last 52-week period, shares are up 9.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/PNNT/earnings">To track all earnings releases for Pennant Park Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pennant Park Investment's Earnings Outlook

Tuesday marks the last chance for investors to receive the next dividend payout from Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>). 
<h3>What's Happening</h3>
The company announced on Thursday that it would pay shareholders a quarterly dividend of 7 cents per share. On Wednesday, Pennant Park Investment will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 7 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Wednesday. Shareholders who own PNNT as of the end of Tuesday's session are eligible to receive the 7 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on December 01, 2023. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To read more news on Pennant Park Investment <a href="https://www.benzinga.com/stock//">click here</a>
<a href="https://www.benzinga.com/calendars/dividends">Click here</a> to visit our Dividends Calendar.

Tuesday Is Your Last Chance To Buy Pennant Park Investment Before The Dividend Payout

By the close of today, November 01, 2023, Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) will issue a dividend payout of $0.07 per share, resulting in an annualized dividend yield of 4.35%. This payout is exclusively for shareholders who held the stock before the ex-dividend date on October 16, 2023.
<h3>Pennant Park Investment Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023-10-16</td>
<td style="text-align: right;">4</td>
<td>$0.07</td>
<td>4.35%</td>
<td>2023-10-03</td>
<td>2023-10-17</td>
<td>2023-11-01</td>
</tr>
<tr>
<td>2023-09-15</td>
<td style="text-align: right;">4</td>
<td>$0.21</td>
<td>12.57%</td>
<td>2023-08-09</td>
<td>2023-09-18</td>
<td>2023-10-02</td>
</tr>
<tr>
<td>2023-06-14</td>
<td style="text-align: right;">4</td>
<td>$0.2</td>
<td>16.39%</td>
<td>2023-05-10</td>
<td>2023-06-15</td>
<td>2023-07-03</td>
</tr>
<tr>
<td>2023-03-15</td>
<td style="text-align: right;">4</td>
<td>$0.18</td>
<td>12.19%</td>
<td>2023-02-08</td>
<td>2023-03-16</td>
<td>2023-04-03</td>
</tr>
<tr>
<td>2022-12-16</td>
<td style="text-align: right;">4</td>
<td>$0.17</td>
<td>10.84%</td>
<td>2022-11-16</td>
<td>2022-12-19</td>
<td>2023-01-03</td>
</tr>
<tr>
<td>2022-09-16</td>
<td style="text-align: right;">4</td>
<td>$0.15</td>
<td>9.1%</td>
<td>2022-08-03</td>
<td>2022-09-19</td>
<td>2022-10-03</td>
</tr>
<tr>
<td>2022-06-16</td>
<td style="text-align: right;">4</td>
<td>$0.14</td>
<td>7.76%</td>
<td>2022-05-04</td>
<td>2022-06-17</td>
<td>2022-07-01</td>
</tr>
<tr>
<td>2022-03-16</td>
<td style="text-align: right;">4</td>
<td>$0.14</td>
<td>7.79%</td>
<td>2022-02-09</td>
<td>2022-03-17</td>
<td>2022-04-01</td>
</tr>
<tr>
<td>2021-12-17</td>
<td style="text-align: right;">4</td>
<td>$0.12</td>
<td>7.09%</td>
<td>2021-12-02</td>
<td>2021-12-20</td>
<td>2022-01-03</td>
</tr>
<tr>
<td>2021-09-16</td>
<td style="text-align: right;">4</td>
<td>$0.12</td>
<td>7.41%</td>
<td>2021-09-02</td>
<td>2021-09-17</td>
<td>2021-10-01</td>
</tr>
<tr>
<td>2021-06-16</td>
<td style="text-align: right;">4</td>
<td>$0.12</td>
<td>7.03%</td>
<td>2021-06-02</td>
<td>2021-06-17</td>
<td>2021-07-01</td>
</tr>
<tr>
<td>2021-03-17</td>
<td style="text-align: right;">4</td>
<td>$0.12</td>
<td>8.54%</td>
<td>2021-03-02</td>
<td>2021-03-18</td>
<td>2021-04-01</td>
</tr>
</tbody>
</table>
When comparing Pennant Park Investment's dividend yield against its industry peers, the company sits comfortably in the middle, with its peer TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) having the highest annualized dividend yield at 16.91%.
<h3>Analyzing Pennant Park Investment Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2023/1698851104_0.png" alt="dividend chart graph" />
As you can see, from 2019 to 2022, investors saw an average decrease in the company's dividend per share, decreasing from $0.72 in 2019 to $0.60 in 2022. This is not favorable for investors as it indicates a decline in the company's dividend payout over the years. Further analysis is recommended to understand the factors contributing to this decrease.
<h3>YoY Earnings Growth For Pennant Park Investment</h3>
<img src="https://www.benzinga.com/files/images/story/2023/1698851104_1.png" alt="earning chart graph" />
Investors can observe a decrease in Pennant Park Investment's earnings per share from $0.71 in 2019 to $0.67 in 2022. This declining earnings trend may be concerning for income-seeking investors, as it indicates a potential impact on the company's cash dividend payouts. A comprehensive analysis is recommended to understand the factors driving this decrease and evaluate its implications on future dividend payments.
<h3>Recap</h3>
This article takes an in-depth look at Pennant Park Investment's recent dividend payout and its implications for shareholders. The company is currently distributing a dividend of $0.07 per share today, translating to an annualized dividend yield of 4.35%.
When comparing Pennant Park Investment's dividend yield against its industry peers, the company sits comfortably in the middle, with its peer TriplePoint Venture Gwth having the highest annualized dividend yield at 16.91%.
The decrease in both dividend per share and earnings per share from 2019 to 2022 for Pennant Park Investment suggests financial challenges, which may require a cautious approach in distributing profits to shareholders.
To stay well-informed about potential changes in financials or dividend disbursements, investors should closely observe the company's performance in the upcoming quarters.
\To stay up-to-date with the companies that are announcing their dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TPVG

Pennant Park Investment Restructures Rewards to Shareholders Amidst Uncertainty

Jose A Briones, Director at Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>), reported a large insider buy on August 16, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001383414/000120919123046048//Archives/edgar/data/1383414/000120919123046048/0001209191-23-046048-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Briones purchased 10,960 shares of Pennant Park Investment. The total transaction amounted to $74,982. 
Pennant Park Investment shares are trading up 0.45% at $6.67 at the time of this writing on Thursday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001383414">Check Out The Full List Of Pennant Park Investment's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Pennant Park Investment Director Trades Company's Stock

<h3>Upgrades</h3>
Ladenburg Thalmann upgraded the previous rating for Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) from Sell to Neutral. Edison Intl earned $1.01 in the second quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $74.92 and a 52-week-low of $54.51. At the end of the last trading period, Edison Intl closed at $69.76. 
For Hannon Armstrong Sustainable Infrastructure Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>), B of A Securities upgraded the previous rating of Neutral to Buy. Hannon Armstrong earned $0.53 in the second quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $44.41 and a 52-week-low of $21.31. Hannon Armstrong closed at $23.12 at the end of the last trading period. 
Janney Montgomery Scott upgraded the previous rating for Shore Bancshares Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHBI#NASDAQ">SHBI</a>) from Neutral to Buy. For the second quarter, Shore Bancshares had an EPS of $0.25, compared to year-ago quarter EPS of $0.39. The current stock performance of Shore Bancshares shows a 52-week-high of $20.49 and a 52-week-low of $10.65. Moreover, at the end of the last trading period, the closing price was at $11.39. 
Oppenheimer upgraded the previous rating for Redfin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) from Underperform to Perform. Redfin earned $0.25 in the second quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $17.68 and a 52-week-low of $3.08. At the end of the last trading period, Redfin closed at $10.16. 
According to Raymond James, the prior rating for CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) was changed from Market Perform to Outperform. CareDx earned $0.18 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.54 and a 52-week-low of $6.22. CareDx closed at $9.35 at the end of the last trading period. 
According to Morgan Stanley, the prior rating for Pharvaris NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>) was changed from Equal-Weight to Overweight. Pharvaris earned $0.69 in the second quarter, compared to $0.40 in the year-ago quarter. The stock has a 52-week-high of $21.71 and a 52-week-low of $1.80. At the end of the last trading period, Pharvaris closed at $18.42. 
RBC Capital upgraded the previous rating for Hexcel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) from Sector Perform to Outperform. In the second quarter, Hexcel showed an EPS of $0.50, compared to $0.33 from the year-ago quarter. The current stock performance of Hexcel shows a 52-week-high of $79.08 and a 52-week-low of $50.25. Moreover, at the end of the last trading period, the closing price was at $69.11. 
For NextDecade Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>), Stifel upgraded the previous rating of Hold to Buy. NextDecade earned $0.23 in the first quarter, compared to $0.14 in the year-ago quarter. The current stock performance of NextDecade shows a 52-week-high of $8.94 and a 52-week-low of $3.92. Moreover, at the end of the last trading period, the closing price was at $5.53. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
According to Laidlaw &amp; Co., the prior rating for Alaunos Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) was changed from Buy to Hold. In the second quarter, Alaunos Therapeutics showed an EPS of $0.04, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.01 and a 52-week-low of $0.38. Alaunos Therapeutics closed at $0.39 at the end of the last trading period. 
According to SVB Leerink, the prior rating for Galecto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) was changed from Outperform to Market Perform. Galecto earned $0.41 in the second quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $3.70 and a 52-week-low of $1.06. At the end of the last trading period, Galecto closed at $2.34. 
For Chicken Soup for the Soul Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>), Craig-Hallum downgraded the previous rating of Buy to Hold. For the second quarter, Chicken Soup for the Soul had an EPS of $1.50, compared to year-ago quarter EPS of $1.28. The stock has a 52-week-high of $13.44 and a 52-week-low of $0.94. At the end of the last trading period, Chicken Soup for the Soul closed at $1.01. 
For Design Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>), Wedbush downgraded the previous rating of Outperform to Neutral. Design Therapeutics earned $0.36 in the second quarter, compared to $0.27 in the year-ago quarter. The stock has a 52-week-high of $26.30 and a 52-week-low of $4.90. At the end of the last trading period, Design Therapeutics closed at $7.33. 
According to Alliance Global Partners, the prior rating for Chicken Soup for the Soul Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) was changed from Buy to Neutral. Chicken Soup for the Soul earned $1.50 in the second quarter, compared to $1.28 in the year-ago quarter. The stock has a 52-week-high of $13.44 and a 52-week-low of $0.94. At the end of the last trading period, Chicken Soup for the Soul closed at $1.01. 
Mizuho downgraded the previous rating for BioXcel Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) from Buy to Neutral. For the second quarter, BioXcel Therapeutics had an EPS of $1.83, compared to year-ago quarter EPS of $1.35. The current stock performance of BioXcel Therapeutics shows a 52-week-high of $34.12 and a 52-week-low of $3.81. Moreover, at the end of the last trading period, the closing price was at $4.33. 
According to Citigroup, the prior rating for Gol Intelligent Airlines Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOL#NYSE">GOL</a>) was changed from Buy to Neutral. In the second quarter, Gol Intelligent Airlines showed an EPS of $0.48, compared to $0.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.59 and a 52-week-low of $2.00. Gol Intelligent Airlines closed at $3.71 at the end of the last trading period. 
For Design Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>), SVB Leerink downgraded the previous rating of Outperform to Market Perform. For the second quarter, Design Therapeutics had an EPS of $0.36, compared to year-ago quarter EPS of $0.27. The current stock performance of Design Therapeutics shows a 52-week-high of $26.30 and a 52-week-low of $4.90. Moreover, at the end of the last trading period, the closing price was at $7.33. 
According to B of A Securities, the prior rating for Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) was changed from Buy to Neutral. Valero Energy earned $5.40 in the second quarter, compared to $11.36 in the year-ago quarter. The stock has a 52-week-high of $160.16 and a 52-week-low of $97.76. At the end of the last trading period, Valero Energy closed at $136.50. 
For PBF Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>), B of A Securities downgraded the previous rating of Buy to Neutral. For the second quarter, PBF Energy had an EPS of $2.29, compared to year-ago quarter EPS of $10.58. The stock has a 52-week-high of $50.43 and a 52-week-low of $27.02. At the end of the last trading period, PBF Energy closed at $49.52. 
According to B of A Securities, the prior rating for Marathon Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) was changed from Buy to Neutral. Marathon Petroleum earned $5.32 in the second quarter, compared to $10.61 in the year-ago quarter. The stock has a 52-week-high of $149.76 and a 52-week-low of $89.41. At the end of the last trading period, Marathon Petroleum closed at $148.54. 
According to B of A Securities, the prior rating for HF Sinclair Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) was changed from Buy to Neutral. For the second quarter, HF Sinclair had an EPS of $2.60, compared to year-ago quarter EPS of $5.59. The current stock performance of HF Sinclair shows a 52-week-high of $66.17 and a 52-week-low of $37.12. Moreover, at the end of the last trading period, the closing price was at $57.95. 
According to RBC Capital, the prior rating for Design Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) was changed from Outperform to Sector Perform. In the second quarter, Design Therapeutics showed an EPS of $0.36, compared to $0.27 from the year-ago quarter. The current stock performance of Design Therapeutics shows a 52-week-high of $26.30 and a 52-week-low of $4.90. Moreover, at the end of the last trading period, the closing price was at $7.33. 
HC Wainwright &amp; Co. downgraded the previous rating for Zynerba Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYNE#NASDAQ">ZYNE</a>) from Buy to Neutral. For the first quarter, Zynerba Pharmaceuticals had an EPS of $0.21, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $1.38 and a 52-week-low of $0.25. At the end of the last trading period, Zynerba Pharmaceuticals closed at $1.35. 
For 22nd Century Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), TD Cowen downgraded the previous rating of Outperform to Market Perform. 22nd Century Group earned $1.40 in the second quarter, compared to $0.95 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.82 and a 52-week-low of $2.10. 22nd Century Group closed at $2.29 at the end of the last trading period. 
According to Citigroup, the prior rating for Agiliti Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) was changed from Buy to Neutral. For the second quarter, Agiliti had an EPS of $0.14, compared to year-ago quarter EPS of $0.19. The current stock performance of Agiliti shows a 52-week-high of $20.11 and a 52-week-low of $10.76. Moreover, at the end of the last trading period, the closing price was at $11.71. 
For Forward Air Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>), Baird downgraded the previous rating of Outperform to Neutral. In the second quarter, Forward Air showed an EPS of $0.91, compared to $2.04 from the year-ago quarter. The current stock performance of Forward Air shows a 52-week-high of $121.38 and a 52-week-low of $72.16. Moreover, at the end of the last trading period, the closing price was at $73.23. 
Truist Securities downgraded the previous rating for Avid Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVID#NASDAQ">AVID</a>) from Buy to Hold. In the second quarter, Avid Technology showed an EPS of $0.22, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $33.41 and a 52-week-low of $19.78. At the end of the last trading period, Avid Technology closed at $26.60. 
For Pennant Park Investment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>), Compass Point downgraded the previous rating of Buy to Neutral. For the third quarter, Pennant Park Investment had an EPS of $0.35, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $7.07 and a 52-week-low of $4.70. At the end of the last trading period, Pennant Park Investment closed at $6.82. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
Loop Capital initiated coverage on Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) with a Buy rating. The price target for Savers Value Village is set to $31.00. In the second quarter, Savers Value Village showed an EPS of $0.22, compared to $0.26 from the year-ago quarter. The current stock performance of Savers Value Village shows a 52-week-high of $26.43 and a 52-week-low of $21.50. Moreover, at the end of the last trading period, the closing price was at $25.70. 
With a Buy rating, B of A Securities initiated coverage on Turnstone Biologics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>). The price target seems to have been set at $18.00 for Turnstone Biologics. The current stock performance of Turnstone Biologics shows a 52-week-high of $13.20 and a 52-week-low of $10.11. Moreover, at the end of the last trading period, the closing price was at $11.73. 
SVB Leerink initiated coverage on Cytokinetics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with an Outperform rating. The price target for Cytokinetics is set to $58.00. For the second quarter, Cytokinetics had an EPS of $1.34, compared to year-ago quarter EPS of $0.23. The current stock performance of Cytokinetics shows a 52-week-high of $55.79 and a 52-week-low of $30.66. Moreover, at the end of the last trading period, the closing price was at $32.10. 
Cantor Fitzgerald initiated coverage on Computer Programs and Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSI#NASDAQ">CPSI</a>) with an Overweight rating. The price target for CPSI is set to $24.00. For the second quarter, CPSI had an EPS of $0.40, compared to year-ago quarter EPS of $0.59. At the moment, the stock has a 52-week-high of $32.86 and a 52-week-low of $19.99. CPSI closed at $20.10 at the end of the last trading period. 
With an Overweight rating, Cantor Fitzgerald initiated coverage on R1 RCM Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCM#NASDAQ">RCM</a>). The price target seems to have been set at $20.00 for R1 RCM. For the second quarter, R1 RCM had an EPS of $0.00, compared to year-ago quarter EPS of $0.07. The current stock performance of R1 RCM shows a 52-week-high of $26.44 and a 52-week-low of $6.71. Moreover, at the end of the last trading period, the closing price was at $16.80. 
With an Overweight rating, Piper Sandler initiated coverage on Turnstone Biologics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>). The price target seems to have been set at $20.00 for Turnstone Biologics. At the moment, the stock has a 52-week-high of $13.20 and a 52-week-low of $10.11. Turnstone Biologics closed at $11.73 at the end of the last trading period. 
With a Buy rating, Roth MKM initiated coverage on New Found Gold Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NFGC#AMEX">NFGC</a>). The price target seems to have been set at $9.00 for New Found Gold. For the first quarter, New Found Gold had an EPS of $0.08, compared to year-ago quarter EPS of $0.14. The current stock performance of New Found Gold shows a 52-week-high of $5.70 and a 52-week-low of $2.93. Moreover, at the end of the last trading period, the closing price was at $4.47. 
Barclays initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with an Overweight rating. The price target for ODDITY Tech is set to $57.00. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. The stock has a 52-week-high of $56.00 and a 52-week-low of $45.66. At the end of the last trading period, ODDITY Tech closed at $46.35. 
JP Morgan initiated coverage on Frontline Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Neutral rating. The price target for Frontline is set to $20.00. In the first quarter, Frontline showed an EPS of $0.87, compared to $0.02 from the year-ago quarter. The stock has a 52-week-high of $19.29 and a 52-week-low of $10.11. At the end of the last trading period, Frontline closed at $17.66. 
JP Morgan initiated coverage on Euronav NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EURN#NYSE">EURN</a>) with an Overweight rating. The price target for Euronav is set to $21.50. At the moment, the stock has a 52-week-high of $21.00 and a 52-week-low of $12.94. Euronav closed at $17.63 at the end of the last trading period. 
Oppenheimer initiated coverage on Knife River Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with an Outperform rating. The price target for Knife River Holding is set to $65.00. Knife River Holding earned $1.00 in the second quarter, compared to $0.68 in the year-ago quarter. The stock has a 52-week-high of $52.40 and a 52-week-low of $33.67. At the end of the last trading period, Knife River Holding closed at $50.55. 
With an Overweight rating, Keybanc initiated coverage on ODDITY Tech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>). The price target seems to have been set at $60.00 for ODDITY Tech. ODDITY Tech earned $0.56 in the second quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $45.66. ODDITY Tech closed at $46.35 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Pennant Park Investment Stock (NYSE:PNNT), Short Interest Report

People Also Watch